The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the public domain.
18 September 2026
DXS INTERNATIONAL PLC (AQSE: DXSP)
Timing of FY Results to 30 April 2026
DXS International plc (AQSE: DXSP), the AQSE Growth Market-quoted healthcare information and digital clinical decision support systems provider, will announce its full-year results on Tuesday 22 September 2026, updated from a prior date of Friday 18 September.
The Directors of DXS International plc accept responsibility for this announcement.
Contacts:
David Immelman, CEO
DXS International plc
www.dxs-systems.com
Tel: 01252 719800
AQSE Corporate Broker and Corporate Advisor
Hybridan LLP
Claire Louise Noyce
Tel: 020 3764 2341
Notes to Editors
About DXS:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.
Attachment
